Emerging markets are benefiting from enhanced healthcare infrastructure, boosting access to CMV diagnostics and treatments. Furthermore, advancements in personalized medicine and vaccine development, ...

In the PARAMEDIC-3 trial conducted in the U.K., the 30-day survival rate was 4.5% when the first attempt at access was intraosseous and 5.1% with the intravenous-first strategy (adjusted OR 0.94, 95% ...

The CMD market is expanding, driven by heightened recognition of the condition, especially among women, and a rise in global risk factors. Advances in imaging technologies such as coronary MRI and PET ...

New York, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Anthelmintic Drugs Market Research Report by Drug Class, by Route of Administration, by Target ...

The blood-brain barrier (BBB) prevents the passage of foreign substances from the blood to the brain's extracellular fluid. Several drugs that permeate through the BBB are compromised, and only an ...

The DBA market is driven by advancements in genetic research and personalized medicine, enhancing diagnostic accuracy and treatment efficacy. Key challenges include limited treatment options and high ...